公开(公告)号：US20220305010A1

公开(公告)日：2022-09-29

申请号：US17088613

申请日：2020-11-04

申请人： METABOMED LTD.

发明人： Philippe NAKACHE ,  Omri Erez ,  Simone Botti ,  Andreas Goutopoulos

IPC分类号： A61K31/501 ,  A61K31/4152 ,  A61K31/4155 ,  A61K31/4439 ,  A61K31/635 ,  A61K31/497 ,  A61K31/422 ,  A61K31/4184 ,  A61K31/4245 ,  A61K31/498 ,  A61P35/04

摘要： The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and drug resistant cancer of various types.

公开(公告)号：US20220257593A1

公开(公告)日：2022-08-18

申请号：US17618157

申请日：2020-06-10

申请人： Visus Therapeutics, Inc.

发明人： Robert P. SAMBURSKY ,  Herbert E. KAUFMAN

IPC分类号： A61K31/498 ,  A61K31/27 ,  A61K31/4178 ,  A61K31/4409 ,  A61K47/18 ,  A61K47/26 ,  A61K47/38 ,  A61P27/02

摘要： Use of topical carbachol in combination with brimonidine to create optically beneficial miosis to temporarily treat presbyopia. A pharmaceutical formulation is used comprising a therapeutically effective amount of carbachol, or a pharmaceutically acceptable salt thereof, in combination with brimonidine, or a pharmaceutically acceptable salt thereof, specifically combined with permeation enhancers and excipients to increase efficacy and reduce ocular surface toxicity and improve tolerability.

公开(公告)号：US20220251049A1

公开(公告)日：2022-08-11

申请号：US17547660

申请日：2021-12-10

申请人： NeuPharma, Inc

发明人： Xiangping QIAN ,  Yong-Liang ZHU

IPC分类号： C07D241/42 ,  A61K45/06 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  A61P35/00 ,  A61K31/498 ,  A61K31/5377 ,  C07D241/44

摘要： Chemical entities based on quinoxaline that are kinase inhibitors are described. Specifically, quinoxaline derivatives of Formula I, containing a diarylamide or diarylurea substructure that inhibit Braf mutant kinase activity, pharmaceutical compositions containing the inhibitor compounds and methods of treatment of cancer comprising administering an effective amount of the Braf inhibitor compound are described.

公开(公告)号：US20220233524A1

公开(公告)日：2022-07-28

申请号：US17699405

申请日：2022-03-21

申请人： Eye Therapies, LLC

发明人： Gerald Horn

IPC分类号： A61K31/498 ,  A61K9/00 ,  A61P27/06 ,  A61K47/26 ,  A61P37/08 ,  A61K47/12 ,  A61K31/5575 ,  A61K31/5355 ,  A61K47/38 ,  A61K47/02 ,  A61K31/4535 ,  A61K31/407 ,  A61K9/08

摘要： The present invention is directed to compositions containing low-dose brimonidine and either a second glaucoma drug, an anti-histamine or non-steroidal anti-inflammatory drug. The present invention is further directed to methods of treating glaucoma or allergies or reducing inflammation by administering compositions of the present invention.

公开(公告)号：US20220202788A1

公开(公告)日：2022-06-30

申请号：US17581219

申请日：2022-01-21

申请人： Loxo Oncology, Inc.

发明人： Mark REYNOLDS ,  Charles Todd EARY

IPC分类号： A61K31/439 ,  A61P35/00 ,  A61K47/10 ,  A61K9/16 ,  A61K31/498 ,  A61K47/26 ,  A61K9/08 ,  A61K9/20 ,  A61K47/12 ,  A61K9/00 ,  A61K47/02 ,  A61K47/38 ,  A61K9/48

摘要： 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.

公开(公告)号：US20220202703A1

公开(公告)日：2022-06-30

申请号：US17439348

申请日：2020-03-12

申请人： Poly-Med, Inc.

发明人： David Roper Ingram ,  Michael Scott Taylor ,  Kara Bethany Acampora ,  Michael Aaron Vaughn ,  David Gravett

IPC分类号： A61K9/00 ,  A61K31/498 ,  A61K47/34 ,  A61K47/44 ,  A61K47/10

摘要： In situ gel-forming compositions are disclosed, which may comprise one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and one or more bioactive agents. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. Methods of using in situ gel-forming composition for various applications are also disclosed

公开(公告)号：US11358961B2

公开(公告)日：2022-06-14

申请号：US16724343

申请日：2019-12-22

申请人： Evrys Bio, LLC

发明人： Stacy Remiszewski ,  Emre Koyuncu ,  Qun Sun ,  Lillian Chiang

IPC分类号： C07D417/14 ,  C07D417/04 ,  C07D491/052 ,  C07D417/06 ,  C07D417/10 ,  A61K31/427 ,  A61K45/06 ,  A61K31/436 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/506 ,  A61K31/4709

摘要： Novel compounds useful for treating and/or preventing HCMV infections are provided.

公开(公告)号：US20220175734A1

公开(公告)日：2022-06-09

申请号：US17618152

申请日：2020-06-10

申请人： Visus Therapeutics, Inc.

发明人： Robert P. SAMBURSKY ,  Herbert E. KAUFMAN

IPC分类号： A61K31/4178 ,  A61K31/27 ,  A61K31/417 ,  A61K31/498 ,  A61K47/26 ,  A61K9/00 ,  A61K9/08 ,  A61P27/10

摘要： Using one or more parasympathomimetic drugs alone or together, or in combination with one or more alpha agonists to create optically beneficial miosis to temporarily create multifocality in a pseudophakic patient to treat presbyopia. A pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, alone or in combination with or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. A method for creating multifocality in a pseudophakic patient, reducing symptoms of presbyopia in a patient having an eye or both eyes through administering to an eye or eyes a pharmaceutically effective amount of the ophthalmic preparation is also disclosed.

公开(公告)号：US20220169685A1

公开(公告)日：2022-06-02

申请号：US17669844

申请日：2022-02-11

申请人： MOREHOUSE SCHOOL OF MEDICINE

发明人： Roger P. SIMON ,  Zhigang XIONG

IPC分类号： C07K14/435 ,  A61K38/17 ,  A61K38/16 ,  A61K31/439 ,  A61K31/4418 ,  A61K31/4965 ,  A61K31/498 ,  A61K45/06

摘要： A system, including methods and compositions, for treatment of ischemia.

公开(公告)号：US20220168298A1

公开(公告)日：2022-06-02

申请号：US17430025

申请日：2020-02-11

申请人： Janssen Pharmaceutica NV

发明人： Anne Elizabeth O'HAGAN ,  Peter Marie Z. DE PORRE ,  Anjali Narayan AVADHANI

IPC分类号： A61K31/498 ,  A61P35/04

摘要： The present invention provides a method for the treatment of cancer with erdafitinib in high-risk patients.